nach oben

Langenbeck's Archives of Surgery

Erschienen in:

01.08.2014 | Review Article

Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making

verfasst von: Irinel Popescu, Traian Dumitrascu

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The surgical approach for hilar cholangiocarcinoma (HC) has largely evolved, and increased resectability rates are reported. Large series of patients with resections for HC were published in the last years, and potential predictors for survival were explored. However, the usefulness of these predictors in clinical decision making is controversial.

Purpose

The aim of the present review is to explore the main prognostic factors after curative-intent surgery for HC, as emerged from the current literature. Furthermore, the impact of these predictors on clinical decision making is assessed.

Conclusion

An aggressive surgical approach has improved the survival rates in patients with HC and implies bile duct resection associated with liver resection and loco-regional lymph node dissection. The AJCC staging system remains the main tool to assess the prognosis after resection of HC. Margin-negative resections and absence of lymph node metastases are the main prognostic factor after curative-intent surgery for HC. Response to chemotherapy is also a prognostic factor. Markers of systemic inflammatory response might predict prognosis of patients with HC, but their usefulness in clinical decision making remains unclear.

Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM (2014) Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr 3:18–34PubMedCentralPubMed

Lafemina J, Jarnagin WR (2012) Surgical management of proximal bile duct cancers. Langenbeck’s Arch Surg 397:869–879CrossRef

Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, Dematteo RP, Gonen M, Endo I, Jarnagin WR (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215:343–355PubMedCrossRef

DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245:755–762PubMedCentralPubMedCrossRef

Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463–473PubMedCentralPubMedCrossRef

Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, Seo DW, Pantongrag-Brown L, Sangchan A, Pisespongsa P, Akaraviputh T, Reddy ND, Maydeo A, Itoi T, Pausawasdi N, Punamiya S, Attasaranya S, Devereaux B, Ramchandani M, Goh KL (2013) Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 28:593–607PubMedCrossRef

Are C, Gonen M, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR (2006) Differential diagnosis of proximal biliary obstruction. Surgery 140:756–763PubMedCrossRef

Dumitrascu T, Ionescu M, Ciurea S, Herlea V, Lupescu I, Popescu I (2010) Klatskin-mimicking lesions—a case series and literature review. Hepatogastroenterology 57:961–967PubMed

Gerhards MF, Vos P, van Gulik TM, Rauws EA, Bosma A, Gouma DJ (2001) Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg 88:48–51PubMedCrossRef

10.

Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI (1957) Sclerosing carcinoma of the major intrahepatic bile ducts. AMA Arch Surg 75:450–460PubMedCrossRef

11.

Klatskin G (1965) Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. an unusual tumor with distinctive clinical and pathological features. Am J Med 38:241–256PubMedCrossRef

12.

Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM (2006) Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol 13:872–880PubMedCrossRef

13.

Furusawa N, Kobayashi A, Yokoyama T, Shimizu A, Motoyama H, Miyagawa S (2014) Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality. World J Surg 38:1164–1176PubMedCrossRef

14.

Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY (2010) Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 17:476–489PubMedCrossRef

15.

Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J (2006) Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 93:1488–1494PubMedCrossRef

16.

Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140PubMedCrossRef

17.

Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, Bresadola F, Calise F, Dalla VR, D'Amico DF, Gennari L, Giulini SM, Guglielmi A, Jovine E, Pellicci R, Pernthaler H, Pinna AD, Puleo S, Torzilli G, Capussotti L, Cillo U, Ercolani G, Ferrucci M, Mastrangelo L, Portolani N, Pulitano C, Ribero D, Ruzzenente A, Scuderi V, Federico B (2012) Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147:26–34PubMedCrossRef

18.

DeOliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA (2011) New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53:1363–1371PubMedCrossRef

19.

Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M, Kokudo N, Miyagawa S, Takada T, Nagino M (2014) Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg 101:79–88PubMedCrossRef

20.

Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M (2009) The concept of perihilar cholangiocarcinoma is valid. Br J Surg 96:926–934PubMedCrossRef

21.

Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, Hayashi H, Motoi F, Egawa S (2010) Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 17:463–469PubMedCrossRef

22.

Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T (2008) Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 15:590–599PubMedCrossRef

23.

Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK (2009) Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298–305PubMedCentralPubMedCrossRef

24.

Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH (1998) Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228:385–394PubMedCentralPubMedCrossRef

25.

de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, Majno P, Hatzaras I, Walters DM, Barbas AS, Mega R, Schulick RD, Choti MA, Geller DA, Barroso E, Mentha G, Capussotti L, Pawlik TM (2012) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 118:4737–4747PubMedCrossRef

26.

Song SC, Choi DW, Kow AW, Choi SH, Heo JS, Kim WS, Kim MJ (2013) Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre. ANZ J Surg 83:268–274PubMedCrossRef

27.

van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven GJ, Lameris JS, Rauws EA, Gouma DJ (2011) Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol 37:65–71PubMedCrossRef

28.

Baton O, Azoulay D, Adam DV, Castaing D (2007) Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg 204:250–260PubMedCrossRef

29.

Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, Kato A, Nakamura S, Omoto H, Nakajima N, Kimura F, Suwa T (1998) Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery 123:131–136PubMedCrossRef

30.

Regimbeau JM, Fuks D, Le Treut YP, Bachellier P, Belghiti J, Boudjema K, Baulieux J, Pruvot FR, Cherqui D, Farges O (2011) Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg 15:480–488PubMedCrossRef

31.

Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, Curley SA (2007) High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 193:702–706PubMedCrossRef

32.

Dumitrascu T, Chirita D, Ionescu M, Popescu I (2013) Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg 17:913–924PubMedCrossRef

33.

Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, Dematteo RP, D'Angelica M, Koea J, Blumgart LH (2005) Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241:703–712PubMedCentralPubMedCrossRef

34.

Chen RF, Li ZH, Zhou JJ, Wang J, Chen JS, Lin Q, Tang QB, Peng NF, Jiang ZP, Zhou QB (2007) Preoperative evaluation with T-staging system for hilar cholangiocarcinoma. World J Gastroenterol 13:5754–5759PubMed

35.

Chen XP, Lau WY, Huang ZY, Zhang ZW, Chen YF, Zhang WG, Qiu FZ (2009) Extent of liver resection for hilar cholangiocarcinoma. Br J Surg 96:1167–1175PubMedCrossRef

36.

Miyazaki M, Kimura F, Shimizu H, Yoshidome H, Otuka M, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 17:470–475PubMedCrossRef

37.

Tan JW, Hu BS, Chu YJ, Tan YC, Ji X, Chen K, Ding XM, Zhang A, Chen F, Dong JH (2013) One-stage resection for Bismuth type IV hilar cholangiocarcinoma with high hilar resection and parenchyma-preserving strategies: a cohort study. World J Surg 37:614–621PubMedCrossRef

38.

van Gulik TM, Ruys AT, Busch OR, Rauws EA, Gouma DJ (2011) Extent of liver resection for hilar cholangiocarcinoma (Klatskin tumor): how much is enough? Dig Surg 28:141–147PubMedCrossRef

39.

Bengmark S, Ekberg H, Evander A, Klofver-Stahl B, Tranberg KG (1988) Major liver resection for hilar cholangiocarcinoma. Ann Surg 207:120–125PubMedCentralPubMedCrossRef

40.

Cannon RM, Brock G, Buell JF (2012) Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB (Oxford) 14:142–149CrossRef

41.

Lim JH, Choi GH, Choi SH, Kim KS, Choi JS, Lee WJ (2013) Liver resection for Bismuth type I and Type II hilar cholangiocarcinoma. World J Surg 37:829–837PubMedCrossRef

42.

Capussotti L, Vigano L, Ferrero A, Muratore A (2008) Local surgical resection of hilar cholangiocarcinoma: is there still a place? HPB (Oxford) 10:174–178CrossRef

43.

Bismuth H, Nakache R, Diamond T (1992) Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 215:31–38PubMedCentralPubMedCrossRef

44.

Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451–458PubMedCentralPubMed

45.

Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ (2009) Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 18:325–337, ixPubMedCrossRef

46.

Salgia RJ, Singal AG, Fu S, Pelletier S, Marrero JA (2014) Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci 59:1048–1054PubMedCrossRef

47.

Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, Schmidt CM, Ball CG, Lillemoe KD (2011) Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB (Oxford) 13:139–147CrossRef

48.

Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS, Chung JB, Kim KS (2012) Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 16:1672–1679PubMedCrossRef

49.

Cheng QB, Yi B, Wang JH, Jiang XQ, Luo XJ, Liu C, Ran RZ, Yan PN, Zhang BH (2012) Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 38:1197–1203PubMedCrossRef

50.

Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H (2004) Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg 240:95–101PubMedCentralPubMedCrossRef

51.

Sano T, Shimada K, Sakamoto Y, Esaki M, Kosuge T (2007) Changing trends in surgical outcomes after major hepatobiliary resection for hilar cholangiocarcinoma: a single-center experience over 25 years. J Hepatobiliary Pancreat Surg 14:455–462PubMedCrossRef

52.

Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T, Makuuchi M (2003) Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 238:73–83PubMedCentralPubMed

53.

Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM, Rikkers LF, Weber SM (2008) Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 248:273–279PubMedCrossRef

54.

Launois B, Campion JP, Brissot P, Gosselin M (1979) Carcinoma of the hepatic hilus. Surgical management and the case for resection. Ann Surg 190:151–157PubMedCentralPubMedCrossRef

55.

Launois B, Terblanche J, Lakehal M, Catheline JM, Bardaxoglou E, Landen S, Campion JP, Sutherland F, Meunier B (1999) Proximal bile duct cancer: high resectability rate and 5-year survival. Ann Surg 230:266–275PubMedCentralPubMedCrossRef

56.

de Jong MC, Hong SM, Augustine MM, Goggins MG, Wolfgang CL, Hirose K, Schulick RD, Choti MA, Anders RA, Pawlik TM (2011) Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch Surg 146:697–703PubMedCentralPubMedCrossRef

57.

Ercolani G, Zanello M, Grazi GL, Cescon M, Ravaioli M, Del GM, Vetrone G, Cucchetti A, Brandi G, Ramacciato G, Pinna AD (2010) Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. J Hepatobiliary Pancreat Sci 17:329–337PubMedCrossRef

58.

Tabata M, Kawarada Y, Yokoi H, Higashiguchi T, Isaji S (2000) Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7:148–154PubMedCrossRef

59.

Bismuth H, Corlette MB (1975) Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 140:170–178PubMed

60.

Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ (2005) Surgical management of hilar cholangiocarcinoma. Ann Surg 241:693–699PubMedCentralPubMedCrossRef

61.

Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S (2003) Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 238:84–92PubMedCentralPubMed

62.

Klempnauer J, Ridder GJ, Von WR, Werner M, Weimann A, Pichlmayr R (1997) Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 15:947–954PubMed

63.

Yubin L, Chihua F, Zhixiang J, Jinrui O, Zixian L, Jianghua Z, Ye L, Haosheng J, Chaomin L (2008) Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol 15:2113–2119PubMedCrossRef

64.

American Joint Committee on Cancer: AJCC (2010) Cancer staging manual, 7th edn. Springer, New YorkCrossRef

65.

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Conci S, Valdegamberi A, Sandri M, Iacono C (2011) Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford) 13:240–245CrossRef

66.

Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ, Prasad KR, Lodge JP (2008) Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 34:787–794PubMedCrossRef

67.

IJitsma AJ, Appeltans BM, de Jong KP, Porte RJ, Peeters PM, Slooff MJ (2004) Extrahepatic bile duct resection in combination with liver resection for hilar cholangiocarcinoma: a report of 42 cases. J Gastrointest Surg 8:686–694PubMedCrossRef

68.

Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, Fung JJ, Starzl TE (1998) Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 187:358–364PubMedCentralPubMedCrossRef

69.

Kobayashi A, Miwa S, Nakata T, Miyagawa S (2010) Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg 97:56–64PubMedCrossRef

70.

Jarnagin WR, Fong Y, Dematteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517PubMedCentralPubMedCrossRef

71.

Zaydfudim VM, Clark CJ, Kendrick ML, Que FG, Reid-Lombardo KM, Donohue JH, Farnell MB, Nagorney DM (2013) Correlation of staging systems to survival in patients with resected hilar cholangiocarcinoma. Am J Surg 206:159–165PubMedCrossRef

72.

Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M (2013) Surgical treatment of perihilar cholangiocarcinoma in octogenarians: a single center experience. J Hepatobiliary Pancreat Sci 20:324–331PubMedCrossRef

73.

Ito K, Ito H, Allen PJ, Gonen M, Klimstra D, D'Angelica MI, Fong Y, Dematteo RP, Brennan MF, Blumgart LH, Jarnagin WR (2010) Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg 251:675–681PubMedCrossRef

74.

Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M (1999) Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 230:663–671PubMedCentralPubMedCrossRef

75.

Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, Heo JS, Choi SH (2012) Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg 36:1112–1121PubMedCrossRef

76.

Fang Y, Gurusamy KS, Wang Q, Davidson BR, Lin H, Xie X, Wang C (2013) Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg 100:1589–1596PubMedCrossRef

77.

Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF (2013) Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 100:274–283PubMedCrossRef

78.

Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, Schwartz LH, Allen P, D'Angelica M, Fong Y, Dematteo RP, Blumgart LH, Jarnagin WR (2009) Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 11:445–451CrossRef

79.

Liu F, Li Y, Wei Y, Li B (2011) Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 56:663–672PubMedCrossRef

80.

Nimura Y (2008) Preoperative biliary drainage before resection for cholangiocarcinoma (Pro). HPB (Oxford) 10:130–133CrossRef

81.

Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kawasaki R (2010) Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci 17:455–462PubMedCrossRef

82.

Wahab MA, Sultan AM, Salah T, Fathy O, Elebidy G, Elshobary M, Shiha O, Rauf AA, Elhemaly M, El-Ghawalby N (2012) Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value? Hepatogastroenterology 59:321–324PubMed

83.

Young AL, Igami T, Senda Y, Adair R, Farid S, Toogood GJ, Prasad KR, Lodge JP (2011) Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford) 13:483–493CrossRef

84.

Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Chen QB, Wu MC (2004) Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 3:453–457PubMed

85.

Anaya DA, Blazer DG, Abdalla EK (2008) Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Interv Radiol 25:110–122CrossRef

86.

Higuchi R, Yamamoto M (2014) Indications for portal vein embolization in perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci

87.

Hong YK, Choi SB, Lee KH, Park SW, Park YN, Choi JS, Lee WJ, Chung JB, Kim KS (2011) The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: a retrospective cohort study. Eur J Surg Oncol 37:237–244PubMedCrossRef

88.

Palavecino M, Abdalla EK, Madoff DC, Vauthey JN (2009) Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am 18:257–267, viiiPubMedCrossRef

89.

Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y (2005) One hundred consecutive hepatobiliary resections for biliary hilar malignancy: preoperative blood donation, blood loss, transfusion, and outcome. Surgery 137:148–155PubMedCrossRef

90.

Dinant S, Gerhards MF, Busch OR, Obertop H, Gouma DJ, van Gulik TM (2005) The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma. HPB (Oxford) 7:263–267CrossRef

91.

Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R (1999) Extended resections for hilar cholangiocarcinoma. Ann Surg 230:808–818PubMedCentralPubMedCrossRef

92.

Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Miyachi M, Kanai M, Uesaka K, Oda K, Rossi RL, Braasch JW, Dugan JM (2000) Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 232:166–174PubMedCentralPubMedCrossRef

93.

Neuhaus P, Jonas S (2000) Surgery for hilar cholangiocarcinoma—the German experience. J Hepatobiliary Pancreat Surg 7:142–147PubMedCrossRef

94.

Neuhaus P, Jonas S, Settmacher U, Thelen A, Benckert C, Lopez-Hanninen E, Hintze RE (2003) Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 388:194–200PubMedCrossRef

95.

Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, Seehofer D (2012) Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 19:1602–1608PubMedCrossRef

96.

Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, Schwartz ME (2008) Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg 196:160–169PubMedCrossRef

97.

Natsume S, Ebata T, Yokoyama Y, Igami T, Sugawara G, Shimoyama Y, Nagino M (2012) Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and comparison with left hepatectomy. Ann Surg 255:754–762PubMedCrossRef

98.

Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Miyazaki M (2010) Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann Surg 251:281–286PubMedCrossRef

99.

Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S (1990) Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 14:535–543PubMedCrossRef

100.

Mizumoto R, Kawarada Y, Suzuki H (1986) Surgical treatment of hilar carcinoma of the bile duct. Surg Gynecol Obstet 162:153–158PubMed

101.

Seehofer D, Thelen A, Neumann UP, Veltzke-Schlieker W, Denecke T, Kamphues C, Pratschke J, Jonas S, Neuhaus P (2009) Extended bile duct resection and [corrected] liver and transplantation in patients with hilar cholangiocarcinoma: long-term results. Liver Transpl 15:1499–1507PubMedCrossRef

102.

Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW (2011) Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 146:683–689PubMedCrossRef

103.

Darwish MS, Heimbach JK, Gores GJ, Rosen CB, Benson JT, Kim WR (2013) Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. Liver Transpl 19:521–528CrossRef

104.

Abbas S, Sandroussi C (2013) Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 15:492–503CrossRef

105.

Wu XS, Dong P, Gu J, Li ML, Wu WG, Lu JH, Mu JS, Ding QC, Zhang L, Ding Q, Weng H, Liu YB (2013) Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg 17:1107–1115PubMedCrossRef

106.

Yu W, Gu Z, Shi S, Shen N, Zhang Y (2014) Effect evaluation of vascular resection for patients with hilar cholangiocarcinoma: original data and meta-analysis. Cell Biochem Biophys

107.

Tamoto E, Hirano S, Tsuchikawa T, Tanaka E, Miyamoto M, Matsumoto J, Kato K, Shichinohe T (2014) Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford) 16:56–61CrossRef

108.

Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q (2011) Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg 28:226–231PubMedCrossRef

109.

Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Nozawa S (2007) Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery 141:581–588PubMedCrossRef

110.

Chatelain D, Farges O, Fuks D, Trouillet N, Pruvot FR, Regimbeau JM (2012) Assessment of pathology reports on hilar cholangiocarcinoma: the results of a nationwide, multicenter survey performed by the AFC-HC-2009 study group. J Hepatol 56:1121–1128PubMedCrossRef

111.

Schiffman SC, Reuter NP, McMasters KM, Scoggins CR, Martin RC (2012) Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J Surg Oncol 105:91–96PubMedCrossRef

112.

Endo I, House MG, Klimstra DS, Gonen M, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR (2008) Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 15:2104–2112PubMedCrossRef

113.

Ruys AT, Kate FJ, Busch OR, Engelbrecht MR, Gouma DJ, van Gulik TM (2011) Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford) 13:881–886CrossRef

114.

Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Nimura Y (2001) Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 233:385–392PubMedCentralPubMedCrossRef

115.

Kurosaki I, Tsukada K, Hatakeyama K, Muto T (1996) The mode of lymphatic spread in carcinoma of the bile duct. Am J Surg 172:239–243PubMedCrossRef

116.

Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 31:1256–1263PubMedCrossRef

117.

Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y (2005) Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 390:104–113PubMedCrossRef

118.

Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K, Nimura Y (2006) Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 244:706–714PubMedCentralPubMedCrossRef

119.

Shingu Y, Ebata T, Nishio H, Igami T, Shimoyama Y, Nagino M (2010) Clinical value of additional resection of a margin-positive proximal bile duct in hilar cholangiocarcinoma. Surgery 147:49–56PubMedCrossRef

120.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRef

121.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T (2009) Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13:1470–1479PubMedCrossRef

122.

Otani K, Chijiiwa K, Kai M, Ohuchida J, Nagano M, Tsuchiya K, Kondo K (2008) Outcome of surgical treatment of hilar cholangiocarcinoma. J Gastrointest Surg 12:1033–1040PubMedCrossRef

123.

Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T (2012) Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg 256:288–296PubMedCrossRef

124.

Gerhards MF, van Gulik TM, Gonzalez GD, Rauws EA, Gouma DJ (2003) Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27:173–179PubMed

125.

Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW (1994) Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 219:267–274PubMedCentralPubMedCrossRef

126.

Todoroki T (2000) Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 47:644–649PubMed

127.

Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL (1995) Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221:788–797PubMedCentralPubMedCrossRef

128.

Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163PubMedCrossRef

129.

Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL (2006) C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 12:5495–5500PubMed

130.

Iwaku A, Kinoshita A, Onoda H, Fushiya N, Nishino H, Matsushima M, Tajiri H (2014) The glasgow prognostic score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Med Oncol 31:787PubMedCrossRef

131.

McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ (2014) Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer

132.

Oshiro Y, Sasaki R, Fukunaga K, Kondo T, Oda T, Takahashi H, Ohkohchi N (2013) Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 20:389–395PubMedCrossRef

Titel: Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making
verfasst von: Irinel Popescu
Traian Dumitrascu
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Langenbeck's Archives of Surgery / Ausgabe 6/2014
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-014-1210-x

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Purpose

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Morbidity of central neck dissection: primary surgery vs reoperation. Results of a case–control study

Inflammatory markers as predictors of surgical site infection after elective colorectal cancer surgery

Micrometastasis of hypopharyngeal cancer

Transoral parathyroid surgery—a new alternative or nonsense?

Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy

Improvement of quality of life in patients with benign goiter after surgical treatment

Update Chirurgie